**Pharmacokinetic Evaluation of a One-Day Treatment Initiation Option for Starting Long-Acting Aripiprazole Lauroxil for Schizophrenia**

# **Supplemental Digital Content 6**

## SUPPLEMENTAL TABLE S2. Adverse Events in ≥2% of Patients Overall

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Patients, n (%)** | **1-Day Initiation AL 441 mg**\* | **1-Day Initiation AL 882 mg**† | **21-Day Initiation AL 441 mg**‡ | **21-Day Initiation AL 882 mg**§ |
| N | 39 | 41 | 40 | 41 |
| Any AE | 26 (66.7) | 28 (68.3) | 24 (60.0) | 28 (68.3) |
| Gastrointestinal disorders  Dyspepsia  Diarrhea  Toothache  Nausea  Vomiting | 9 (23.1)  3 (7.7)  1 (2.6)  1 (2.6)  2 (5.1)  0 | 4 (9.8)  2 (4.9)  2 (4.9)  0  0  2 (4.9) | 6 (15.0)  1 (2.5)  1 (2.5)  3 (7.5)  0  1 (2.5) | 8 (19.5)  3 (7.3)  1 (2.4)  1 (2.4)  2 (4.9)  1 (2.4) |
| General disorders and administration-site conditions‖  Injection-site pain  Injection-site induration  Fatigue  Injection-site swelling | 10 (25.6)  9 (23.1)  2 (5.1)  0  0 | 9 (22.0)  8 (19.5)  2 (4.9)  1 (2.4)  0 | 14 (35.0)  11 (27.5)  2 (5.0)  2 (5.0)  2 (5.0) | 10 (24.4)  9 (22.0)  1 (2.4)  1 (2.4)  1 (2.4) |
| Immune system disorders | 0 | 3 (7.3) | 1 (2.5) | 0 |
| Infections and infestations  URTI  Nasopharyngitis | 3 (7.7)  0  1 (2.6) | 7 (17.1)  2 (4.9)  2 (4.9) | 5 (12.5)  2 (5.0)  0 | 5 (12.2)  3 (7.3)  2 (4.9) |
| Injury, poisoning, and procedural complications  Fall | 2 (5.1)  1 (2.6) | 2 (4.9)  1 (2.4) | 4 (10.0)  1 (2.5) | 3 (7.3)  1 (2.4) |
| Investigations  Weight increased  Weight decreased | 6 (15.4)  5 (12.8)  1 (2.6) | 7 (17.1)  4 (9.8)  2 (4.9) | 4 (10.0)  2 (5.0)  0 | 5 (12.2)  1 (2.4)  2 (4.9) |
| Musculoskeletal and connective tissue disorders | 4 (10.3) | 3 (7.3) | 3 (7.5) | 1 (2.4) |
| Nervous system disorders  Headache  Akathisia | 8 (20.5)  3 (7.7)  1 (2.6) | 9 (22.0)  3 (7.3)  3 (7.3) | 6 (15.0)  5 (12.5)  0 | 7 (17.1)  5 (12.2)  2 (4.9) |
| Psychiatric disorders  Insomnia  Anxiety | 6 (15.4)  2 (5.1)  2 (5.1) | 5 (12.2)  2 (4.9)  4 (9.8) | 4 (10.0)  3 (7.5)  2 (5.0) | 5 (12.2)  3 (7.3)  0 |
| Respiratory, thoracic, and mediastinal disorders | 2 (5.1) | 2 (4.9) | 1 (2.5) | 1 (2.4) |
| Vascular disorders  Hypertension | 0  0 | 1 (2.4)  1 (2.4) | 0  0 | 3 (7.3)  3 (7.3) |

AE, adverse event; AL, aripiprazole lauroxil; ALNCD, aripiprazole lauroxil NanoCrystal dispersion; ISR, injection-site reaction; URTI, upper respiratory tract infection.

\*30 mg oral aripiprazole plus ALNCD (gluteal) plus AL 441 mg (deltoid) on Day 1 followed by oral placebo for 20 days.

†30 mg oral aripiprazole plus ALNCD (gluteal) plus AL 882 mg (contralateral gluteal) on Day 1 followed by oral placebo for 20 days.

‡15 mg oral aripiprazole plus placebo injection (gluteal) plus AL 441 mg (deltoid) on Day 1 followed by 20 days of 15 mg oral aripiprazole.

§15 mg oral aripiprazole plus placebo injection (gluteal) plus AL 882 mg (contralateral gluteal) on Day 1 followed by 20 days of 15 mg oral aripiprazole.

‖A breakdown of ISRs by injected product is included in Table 2.